Literature DB >> 23616066

Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted?

S Leoni1, F Piscaglia, A Granito, A Borghi, M Galassi, S Marinelli, E Terzi, L Bolondi.   

Abstract

PURPOSE: To assess the impact of different vascular patterns at contrast-enhanced ultrasound (CEUS) on the characterization of small liver nodules (10-30 mm) in cirrhosis and to determine whether primary nodules and recurrent nodules (after a previously treated hepatocellular carcinoma) display variations in enhancement pattern.
MATERIALS AND METHODS: A total of 135 cirrhotic patients were evaluated. A diagnosis of hepatocellular carcinoma (HCC) was established according to AASLD Guidelines, based on imaging (computed tomography and/or magnetic resonance) or liver biopsy. All patients underwent CEUS. Different CEUS patterns were evaluated in terms of diagnostic accuracy: HYPER-HYPO: Arterial hyperenhancement followed by washout (hypoechoic appearance compared with surrounding parenchyma) in late phase; HYPER-ISO: Arterial hyperenhancement followed by isoenhancement (isoechoic appearance) in late phase; ISO-ISO: Isoenhancement in all vascular phases.
RESULTS: A total of 155 consecutive primary (n = 90) or recurrent (n = 65) nodules were detected. HCC was diagnosed in 127 nodules (71 primary, 56 recurrent). A characteristic HYPER-HYPO CEUS pattern was revealed in 52/127 (40.9%) HCCs (31 primary, 21 recurrent) giving a positive predictive value (PPV) of 98% (97% primary, 100% recurrent) and an accuracy of 51% (54% primary, 46% recurrent). A HYPER-ISO pattern was noted in 46 HCCs (31 primary, 15 recurrent). Assuming this pattern to also be indicative of HCC, the PPV and accuracy were 94% (93% primary, 97% recurrent) and 77% (84% primary, 68% recurrent), respectively. An ISO-ISO pattern was present in 29 HCCs (9 primary, 20 recurrent) and 22 non-HCCs (14 primary, 8 recurrent).
CONCLUSION: These data confirm that the HYPER-HYPO pattern at CEUS is definitely diagnostic for HCC in cirrhosis and that the HYPER-ISO pattern has a similar PPV, indicating that this pattern is highly suspicious for HCC. The ISO-ISO pattern was found in > 50% of recurrent nodules and indicates a high risk of HCC. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23616066     DOI: 10.1055/s-0033-1335024

Source DB:  PubMed          Journal:  Ultraschall Med        ISSN: 0172-4614            Impact factor:   6.548


  21 in total

1.  Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma.

Authors:  Vincenzo O Palmieri; Daniela Santovito; Giuseppe Marano; Francesco Minerva; Lara Ricci; Felicia D'Alitto; Giuseppe Angelelli; Giuseppe Palasciano
Journal:  Radiol Med       Date:  2015-01-20       Impact factor: 3.469

Review 2.  Contrast-enhanced ultrasound in liver cancer.

Authors:  Simona Leoni; Ilaria Serio; Anna Pecorelli; Sara Marinelli; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2015-01-12

3.  Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS.

Authors:  Barbara Schellhaas; Matthias Hammon; Deike Strobel; Lukas Pfeifer; Christian Kielisch; Ruediger S Goertz; Alexander Cavallaro; Rolf Janka; Markus F Neurath; Michael Uder; Hannes Seuss
Journal:  Eur Radiol       Date:  2018-04-19       Impact factor: 5.315

4.  Characterization of Focal Liver Lesions Indistinctive on B Mode Ultrasound: Benefits of Contrast-Enhanced Ultrasound.

Authors:  Yi Dong; Feng Mao; Jiaying Cao; Peili Fan; Wen-Ping Wang
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

5.  Diagnostic value of contrast-enhanced ultrasound in hepatocellular carcinoma: a meta-analysis with evidence from 1998 to 2016.

Authors:  Juanjuan Zhang; Yanyan Yu; Ying Li; Lunshou Wei
Journal:  Oncotarget       Date:  2017-08-07

Review 6.  Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system.

Authors:  Tae Kyoung Kim; Seung Yeon Noh; Stephanie R Wilson; Yuko Kono; Fabio Piscaglia; Hyun-Jung Jang; Andrej Lyshchik; Christoph F Dietrich; Juergen K Willmann; Alexander Vezeridis; Claude B Sirlin
Journal:  Clin Mol Hepatol       Date:  2017-09-15

7.  Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients.

Authors:  Vincent Schwarze; Constantin Marschner; Wiebke Völckers; Sergio Grosu; Giovanna Negrão de Figueiredo; Johannes Rübenthaler; Dirk-André Clevert
Journal:  J Int Med Res       Date:  2020-06       Impact factor: 1.671

8.  Contrast-Enhanced Ultrasound to Monitor Early Recurrence of Primary Hepatocellular Carcinoma after Curative Treatment.

Authors:  Lian-Feng Liu; Zhan-Ling Ding; Jian-Hong Zhong; Hong-Xue Li; Jun-Jie Liu; Hang Li; Le-Qun Li
Journal:  Biomed Res Int       Date:  2018-11-07       Impact factor: 3.411

Review 9.  CT/MRI LI-RADS v2018 vs. CEUS LI-RADS v2017-Can Things Be Put Together?

Authors:  Cosmin Caraiani; Bianca Boca; Vlad Bura; Zeno Sparchez; Yi Dong; Christoph Dietrich
Journal:  Biology (Basel)       Date:  2021-05-06

Review 10.  Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence.

Authors:  Alessandra Mangia; Davide Bellini; Umberto Cillo; Andrea Laghi; Giuseppe Pelle; Vanna Maria Valori; Eugenio Caturelli
Journal:  BMC Gastroenterol       Date:  2020-08-03       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.